HomeFinTechClarity Pharmaceuticals: Receives $3.26m R&D refund

Clarity Pharmaceuticals: Receives $3.26m R&D refund

Date:

UK Tribunal Rules Visa and Mastercard Interchange Fees Breach Competition Law

Landmark decision finds payment giants’ multilateral interchange fees unlawful,...

UK Tribunal Rules Visa and Mastercard Fees Violate Competition Law

Landmark Decision Could Reshape Payment Processing Landscape Highlights: The UK...

Belgium Prosecutors Investigate Worldline Local Unit for Potential Misconduct

An In-Depth Look into the Probe and Its Implications...

Clarity Pharmaceuticals Receives $3.26m R&D refund

  • Clarity Pharmaceuticals (CU6) has received a research and development (R&D) tax refund of more than $3.26 million for FY21
  • The refund is part of The Australian Federal Government’s R&D tax incentive, recognising the R&D undertaken by Clarity in the radiopharmaceutical field
  • The R&D tax incentive is a program by the Australian Federal Government the encourages companies to engage and invest in R&D activities
  • Clarity will use the $3.26 million to further finance the development of its Targeted Copper Theranostics (TCT) platform of products for various cancer indications
  • Shares in Clarity are trading up 2.84 per cent to 72.5 cents
Exit mobile version